S. 3302: Mikaela Naylon Give Kids a Chance Act of 2025

119th Congress · introduced 2025-12-02 · Health · Latest: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

federal

Follow this bill, step by step

Where it came from: introduced 2025-12-02 · official record
Who proposed it: Sen. Mullin, Markwayne [R-OK] · what a sponsor is
What happened next: no floor votes in our records yet. Why?
Where it stands now: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Not final yet: this can still change. We check for updates every day.
If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Mikaela Naylon Give Kids a Chance Act of 2025

Plain summary

Mikaela Naylon Give Kids a Chance Act of 2025 This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer. The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs. The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2030. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024. GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.

Congressional Research Service summary (Introduced in Senate), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Mikaela Naylon Give Kids a Chance Act of 2025

Source: Congressional Research Service summary (Introduced in Senate)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Sen. Mullin, Markwayne [R-OK] · 37 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Michael F. Bennet (D-CO), Amy Klobuchar (D-MN), Jeanne Shaheen (D-NH), Roger Marshall (R-KS), Rick Scott (R-FL), Susan M. Collins (R-ME), Christopher A. Coons (D-DE), Shelley Moore Capito (R-WV), Mark Kelly (D-AZ), Jon Husted (R-OH), Andy Kim (D-NJ), Tim Sheehy (R-MT), Ashley Moody (R-FL), John W. Hickenlooper (D-CO), Tammy Duckworth (D-IL), John Boozman (R-AR), Adam B. Schiff (D-CA), John Kennedy (R-LA), Jack Reed (D-RI), Eric Schmitt (R-MO), Edward J. Markey (D-MA), Cory A. Booker (D-NJ), James C. Justice (R-WV), Ted Budd (R-NC), Kirsten E. Gillibrand (D-NY), Elissa Slotkin (D-MI), Steve Daines (R-MT), Mark R. Warner (D-VA), Richard Blumenthal (D-CT), John R. Curtis (R-UT), Deb Fischer (R-NE), Raphael G. Warnock (D-GA), Martin Heinrich (D-NM), Jim Banks (R-IN), David McCormick (R-PA), Chris Van Hollen (D-MD), Ruben Gallego (D-AZ)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (1)

Bill: A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).

Plain meanings written from linked sources. All words.

Sources

Congressional Research Service summary (Introduced in Senate)
Congress.gov
Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-119s3302.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/119/s>

Record fed-us-cong119-s3302 · catalog fed-us-congress-bills-cong119 · updated 2026-11-03 by psicol fed-bills